You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Eritoran


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Eritoran?

Eritoran is an investigational drug.

There have been 5 clinical trials for Eritoran. The most recent clinical trial was a Phase 3 trial, which was initiated on April 11th 2016.

The most common disease conditions in clinical trials are Insulin Resistance, Hypersensitivity, and Toxemia. The leading clinical trial sponsors are Eisai Inc., The University of Texas Health Science Center at San Antonio, and MJM Bonten.

There are twenty-four US patents protecting this investigational drug and four hundred and fifty-four international patents.

Recent Clinical Trials for Eritoran
TitleSponsorPhase
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaAustralian and New Zealand Intensive Care Research CentrePhase 4
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaBerry ConsultantsPhase 4
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaGlobal Coalition for Adaptive ResearchPhase 4

See all Eritoran clinical trials

Clinical Trial Summary for Eritoran

Top disease conditions for Eritoran
trials000111112222Insulin ResistanceHypersensitivityToxemiaSepsis[disabled in preview]
Top clinical trial sponsors for Eritoran
trials000111112222Eisai Inc.The University of Texas Health Science Center at San AntonioMJM Bonten[disabled in preview]

See all Eritoran clinical trials

US Patents for Eritoran

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Eritoran ⤷  Subscribe Combination therapy for inducing immune response to disease IBC Pharmaceuticals, Inc. (Morris Plains, NJ) ⤷  Subscribe
Eritoran ⤷  Subscribe Methods for treating renal disease Beth Israel Deaconess Medical Center, Inc. (Boston, MA) ⤷  Subscribe
Eritoran ⤷  Subscribe Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors IBC Pharmaceuticals, Inc. (Morris Plains, NJ) ⤷  Subscribe
Eritoran ⤷  Subscribe Combination therapy for inducing immune response to disease IBC Pharmaceuticals, Inc. (Morris Plains, NJ) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 4 of 4 entries

International Patents for Eritoran

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Eritoran Australia AU2014228886 2033-03-15 ⤷  Subscribe
Eritoran Canada CA2942514 2033-03-15 ⤷  Subscribe
Eritoran European Patent Office EP2970428 2033-03-15 ⤷  Subscribe
Eritoran Hong Kong HK1220699 2033-03-15 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 4 of 4 entries

Eritoran: Development Update and Market Projections

Introduction

Eritoran, also known as E5564, is an investigational drug developed by Eisai Co., Ltd. as a Toll-Like Receptor 4 (TLR4) antagonist. Here, we will delve into the development history, current status, and market projections for this drug candidate.

Mechanism of Action

Eritoran is a structural analogue of Lipid A, an activator of endotoxins found in bacterial cell walls. It works by inhibiting the activation of TLR4, a key receptor involved in the inflammatory response and cytokine signaling pathways. This mechanism is crucial in potentially suppressing the severe inflammation and cytokine storms associated with conditions like sepsis and COVID-19[1][4].

Development History

Early Clinical Trials

Eritoran was initially developed as a therapeutic agent for severe sepsis. In a Phase II dose-ascending study, it showed promising results with a lower mortality rate compared to the placebo group, although the trial was not large enough to conclusively evaluate mortality reduction[3].

Phase III Clinical Trials

The Phase III global ACCESS study, however, did not meet its primary endpoint of reducing 28-day all-cause mortality in patients with severe sepsis. Despite this setback, Eisai continued to analyze the data to determine the future of the eritoran development program[3].

Recent Developments

COVID-19 Trials

Eritoran has been included in the REMAP-COVID trial, a randomized, embedded, multifactorial, adaptive platform trial designed to evaluate multiple interventions for the treatment of patients hospitalized with COVID-19. This trial aims to assess whether eritoran can improve health outcomes by suppressing the inflammatory response and cytokine storms associated with severe COVID-19[1].

Animal Models

Recent studies have shown that eritoran can rescue infection and trauma-induced inflammatory damage in animal models. For example, it has been effective in reducing inflammation-derived liver damage, gut permeability, and interleukin-6 (IL-6) expression in mouse models of hemorrhagic shock and resuscitation. Additionally, eritoran has demonstrated efficacy in mitigating moribundity in a mouse model of sterile, trauma-induced systemic inflammation[4].

Safety Profile

Eritoran has been observed to be safe in 14 clinical studies, including the large Phase III randomized trial in severe sepsis. This safety profile is a positive indicator for its potential use in other inflammatory conditions[1].

Market Projections

Current Market Status

Despite the failure in the Phase III sepsis trial, eritoran's potential in other therapeutic areas, such as COVID-19 and trauma-induced inflammation, keeps it relevant in the market. The drug's inclusion in innovative platform trials like REMAP-COVID highlights its ongoing importance in the pharmaceutical landscape[1].

Future Market Potential

The global market for anti-inflammatory drugs is substantial and growing, driven by the increasing incidence of inflammatory diseases and the need for effective treatments. If eritoran proves successful in ongoing or future trials, it could capture a significant share of this market. However, its success will depend on the outcomes of these trials and the ability to secure regulatory approvals[5].

Challenges and Opportunities

Regulatory Hurdles

The failure to meet the primary endpoint in the Phase III sepsis trial has delayed regulatory filing plans. However, ongoing trials and further analysis may provide new avenues for regulatory approval, particularly if eritoran demonstrates efficacy in other conditions[3].

Competitive Landscape

The anti-inflammatory drug market is highly competitive, with several established and investigational drugs. Eritoran's unique mechanism of action as a TLR4 antagonist could differentiate it from other treatments, but it must demonstrate clear clinical benefits to gain market traction[5].

Key Takeaways

  • Mechanism of Action: Eritoran inhibits TLR4 activation, potentially suppressing severe inflammation and cytokine storms.
  • Development History: Initially developed for severe sepsis, with mixed results in clinical trials.
  • Recent Developments: Included in REMAP-COVID trial and shown efficacy in animal models of trauma-induced inflammation.
  • Safety Profile: Observed to be safe in multiple clinical studies.
  • Market Projections: Potential in growing anti-inflammatory drug market, contingent on successful trial outcomes and regulatory approvals.

FAQs

What is Eritoran?

Eritoran is an investigational drug developed by Eisai Co., Ltd. as a Toll-Like Receptor 4 (TLR4) antagonist.

What was the outcome of the Phase III sepsis trial for Eritoran?

The Phase III global ACCESS study did not meet its primary endpoint of reducing 28-day all-cause mortality in patients with severe sepsis[3].

Is Eritoran being tested for COVID-19?

Yes, Eritoran is being evaluated in the REMAP-COVID trial as a potential therapeutic agent for patients hospitalized with COVID-19[1].

What are the potential therapeutic areas for Eritoran beyond sepsis?

Eritoran is being explored for its potential in treating trauma-induced inflammation and other inflammatory conditions, including COVID-19[1][4].

What are the regulatory challenges facing Eritoran?

Eritoran's regulatory filing plans were delayed due to the failure in the Phase III sepsis trial. Future regulatory approvals will depend on the outcomes of ongoing and future trials[3].

Sources

  1. Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial. Amgen Newsroom.
  2. Eritrea Economic Outlook. African Development Bank Group.
  3. Phase III Study Finds Eisai's Eritoran Fails to Reduce Mortality in Severe Sepsis. Genetic Engineering & Biotechnology News.
  4. Optimization of a Lethal, Combat-Relevant Model of Sterile Trauma-Induced Systemic Inflammation. Military Medicine.
  5. Global and China Eritoran Industry Market Research Report. Global Market Monitor.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.